Nanoscope Therapeutics Inc.
Samarendra Mohanty is currently serving as the Chief Scientific Officer at Nanoscope Therapeutics Inc. since June 2021. Previously, Samarendra held the same position at NanoScope Technologies, LLC since January 2016. Samarendra's responsibilities include leading efforts for clinical translation of technologies developed in NanoScope laboratory for early cancer detection, vision restoration in RP/AMD patients, and development of technologies for pain and cancer control. Samarendra Mohanty holds a Ph.D. from the Indian Institute of Science (IISc) and an M.Tech from the Indian Institute of Technology, Delhi.
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa